Sign In
Buy SAVA
$1.96
+0 (+0%)
At Close: Jun 03, 2026
Why Is Cassava Sciences (SAVA) Stock Up 15% Today?
02:00pm, Tuesday, 09'th May 2023
One of the stocks most in focus today for investors is Cassava Sciences (NASDAQ: SAVA ). Shares of SAVA stock have surged more than 15% as investors digest some promising news about the company's lea
Buy Cassava Sciences For Imminent Data Readout
01:17pm, Wednesday, 26'th Apr 2023
Buy Cassava Sciences For Imminent Data Readout.
Cassava Sciences to Present at the 2023 H.C. Wainwright Investor Conference
09:12am, Wednesday, 26'th Apr 2023
AUSTIN, Texas, April 26, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced that Remi Barbier, Presi
Strong Small-Cap Insider Buys: Q1 2023
12:15am, Wednesday, 26'th Apr 2023
Strong Small-Cap Insider Buys: Q1 2023.
3 Short-Squeeze Stocks to Keep on Your Radar
09:45am, Thursday, 09'th Mar 2023
Short-squeezes have been making headlines in stock trading as an increasingly popular phenomenon. A short squeeze occurs when investors who have bet against a company's stock (by “shorting” it) ar
Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock
09:35am, Thursday, 09'th Mar 2023
Cassava Sciences (NASDAQ: SAVA ) stock rose 11% overnight after director Richard Barry said he bought shares worth $2.3 million. The company is working on an Alzheimer's drug called Simufilam.
Cassava Sciences stock price outlook is bearish despite insider buy
01:39am, Thursday, 09'th Mar 2023
Cassava Sciences (NASDAQ: SAVA) stock price has been in a steep sell-off in the past few months as the enthusiasm of its pipeline wanes. Shares of the biopharmaceutical company were trading at $24.9 o
Cassava Sciences: Open Label Study Data Unconvincing But Indicative Of Good Things
07:29am, Sunday, 05'th Mar 2023
Cassava Sciences' phase 2 data was from a nonrandomized trial, therefore unconvincing. However, it indicated drug efficacy quite strongly.
Cassava Sciences Stock Undervalued with Its $124 Price Target?
02:01am, Tuesday, 31'st Jan 2023
Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a clinical-stage biotechnology firm that develops d
Cassava Sciences' Data Once Again Misunderstood
11:37am, Friday, 27'th Jan 2023
Cassava Sciences' Simufilam staved off cognitive decline in mild Alzheimer's disease. The market reacted negatively anyway.
Cassava Sciences: Data For Mild Alzheimer's Disease Patients Provides Good Risk/Reward Profile
02:01pm, Thursday, 26'th Jan 2023
Cassava Sciences released data for over 200 patients in an open-label trial at 12 months. The mild AD subgroup performed unprecedentedly.
Why Is Cassava Sciences (SAVA) Stock Down 20% Today?
02:47pm, Tuesday, 24'th Jan 2023
One of the biggest decliners in today's market is Cassava Sciences (NASDAQ: SAVA ). Shares of SAVA stock declined more than 20% at today's trough on the company's announced mid-stage results for its
Cassava Plummets As 'Highly Desirable' Alzheimer's Results Don't Cut It With Investors
12:10pm, Tuesday, 24'th Jan 2023
Cassava disappointed Tuesday with midstage results for its oral Alzheimer's treatment and SAVA stock plummeted by a double-digit percentage. The post Cassava Plummets As 'Highly Desirable' Alzheimer's
Is a Short Squeeze Coming in Cassava Sciences (SAVA) Stock?
03:39pm, Wednesday, 11'th Jan 2023
Amid surging interest in a wide swath of meme stocks today, retail investors are once again seeing traction in trading unpopular names. That said, other companies many may not necessarily associate wi
6 Favorite Biotech Bets For 2023
10:48am, Monday, 09'th Jan 2023
Biotechnology has often been among the most popular sectors in the MoneyShow Top Picks report, our annual survey of the nation's leading newsletter advisors. This year's report is no exception; here's
